News

Hologic has received FDA approval of its AI-based solution designed to speed up interpretation times for digital breast tomosynthesis (DBT) exams.

As AI technologies have continued to evolve all over the world, it has become more and more evident that proper regulation is necessary.

Nala, a Riyadh, Saudi Arabia-based digital health company, has launched a new AI platform for medical diagnosis. According to Nala, it is the first platform to provide users with diagnoses in Arabic.

Working closely with AI has led researchers from one institution to embrace a familiar piece of technology that may surprise many of their peers: the USB drive.

At the Voice Preservation Clinic in Boston, researchers are now using AI technology to reconstruct the voices of patients at risk of losing the ability to speak.  

Gilead Sciences, a Foster City, California-based biopharmaceutical company, is scheduled to present new AI-powered research related to nonalcoholic steatohepatitis (NASH) at The Liver Meeting 2019 in Boston.

Deep learning techniques have shown potential to change cardiac MRI forever, according to a new analysis published in the American Journal of Roentgenology. However, the authors wrote, it is also important to remember deep learning’s current limitations.

PathAI, a Boston-based AI technology company focused on pathology solutions, announced it has raised $75 million in Series B funding.

RadNet has announced a new partnership with Santa Clara, California-based Whiterabbit.ai to improve mammography screening rates and breast cancer care through the use of AI and other advanced technologies.

It is traditionally believed that men and women experience angina—the pain associated with coronary artery disease—in different ways, with men feeling it in their chest and women feeling it in their arms and back.

Radiologists are in a position to demonstrate their value and lead the implementation of AI in healthcare—but keeping up with these evolving technologies is easier said than done.

PathAI, a Boston-based healthcare technology company, has found that AI can help specialists quantify PD-L1 expression on both tumor cells and immune cells.